Dermatology

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.